Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs ProShares Ultra Semiconductors — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while ProShares Ultra Semiconductors trades at $80.98 (market cap $2.80B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 467,963). Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ProShares Ultra Semiconductors for 30 Days on average.
| ORKA | USD | |
|---|---|---|
Market Cap | $5.08B | $2.80B |
Volume | 685,276 | 467,963 |
Sector | Health | Leveraged / Inverse |
52-Week High | $113.08 | $113.53 |
52-Week Low | $26.19 | $43.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $4.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USD stock trades at $91.26 with a modest 0.26% daily gain, showing neutral momentum amid bearish technical signals. The company declared a $0.13 dividend for H2-2026, payable September 29, 2026. Technical indicators show mixed signals with moving averages bearish but oscillators neutral, while support sits at $90 and resistance at $93.
Fundamental data remains limited with key ratios unavailable, requiring deeper financial review. The stock faces headwinds from bearish technical trends but maintains dividend distribution. Investment appeal hinges on upcoming financial disclosures and market sentiment shifts amid current neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
